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AML Acute myeloid leukemia 
APC Antigen-presenting cell 
BCP-ALL B-cell precursor acute lymphoblastic leukemia 
CAR Chimeric antigen receptor 
Cas9 CRISPR-associated protein 9 
CD Cluster of differentiation 
CD200R CD200 receptor 
CEACAM-1 Carcinoembryonic antigen-related cell adhesion molecule 1 
CRISPR Clusters of regularly interspaced short palindromic repeats 
CRS Cytokine release syndrome 
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gRNA Guide RNA 
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2. Introductory summary  
2.1 Challenges for successful CAR T-cell therapy 
The clinical success of autologous T cells genetically engineered to express a chimeric antigen 
receptor (CAR) against CD19 has revolutionized the treatment of certain cancer types and 
provides a curative treatment option for patients with otherwise dismal prognosis (1, 2). CD19 
CAR T cells are usually produced by transducing T cells of the patient with a retro- or lentiviral 
construct encoding for an anti-CD19 single chain variable fragment (scFv) fused to costimulatory 
domains (i.e. CD28 or 4-1BB) and CD3zeta as part of the T-cell receptor (TCR) complex (3). 
Clinical studies led to FDA (U.S. Food and Drug Administration) and EMA (European Medicines 
Agency) approval of CD19 CAR T cells for the treatment of advanced B-cell malignancies in 2018 
(4, 5). Nevertheless, despite >90% initial response rates in pediatric patients with 
relapsed/refractory B-cell precursor acute lymphoblastic leukemia (BCP-ALL), long-term 
remission rates dropped to about 50% in clinical studies due to relapse after CAR T-cell treatment 
(6, 7). Moreover, successful treatment with CAR T cells can be hampered by a variety of technical 
and biological challenges (figure 1): 1) Production failure of CAR T cells has been reported in up 
to 9% of the cases (8). 2) Antigen escape such as down-regulation of CD19 or outgrowth of CD19 
splice variants can result in CD19- relapse (9, 10). 3) Toxicity of CD19 CAR T cells, in particular 
cytokine release syndrome (CRS) and neurotoxicity, can limit applicability (7). 4) Exhaustion, in-
sufficient expansion and decreased persistence of CAR T cells due to both, T-cell intrinsic and 
extrinsic factors, can lead to CD19+ relapse (11). 5) CAR T-cell therapy of solid tumors remains 
an unmet challenge due to lack of suitable antigens, tumor heterogeneity and difficulties in T-cell 
tumor invasion and persistence caused by the immune-suppressive tumor microenvironment 
(12). 
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Figure 1: Challenges for CAR T-cell therapy. Created with BioRender.com. 
This thesis addresses two of the major challenges. The first part will investigate how to produce 
a highly functional, standardized CAR T-cell product with favorable T-cell phenotype from 
peripheral blood of pediatric leukemia patients. The second part will evaluate the interaction of T 
cells with leukemic cells and introduces examples for how to improve current CAR T-cell therapies 
to break leukemia-mediated resistance. 
2.2 Paper I: Automated CAR T-cell manufacturing for pediatric 
patients 
2.2.1 Introduction 
Manufacturing of CAR T cells is a time-consuming and complex procedure typically involving T-
cell isolation, activation, lenti- or retroviral transduction and expansion (3). Before 2018, most of 
the protocols for large scale CAR T-cell production involved large culture flasks (i.e. G-Rex flasks), 
bioreactors or bags for expansion and a variety of open hands-on steps (13, 14). In order to 
standardize the production, Miltenyi Biotec had developed the CliniMACS Prodigy, a closed GMP-
compatible (Good Manufacturing Practice) system for clinical scale manufacturing of CAR T cells 
(15, 16). The system had been tested and optimized using cell products from healthy donors but 
hadn’t been tested with samples from pediatric leukemia patients yet. Thus, we aimed to test the 
process using 100-120 ml of peripheral blood from patients who were recently diagnosed with 
leukemia. Moreover, as studies suggested that CAR T-cell proliferation and persistence in the 
patients are crucial for a beneficial long-term outcome (17), we investigated the phenotype and 
expression level of exhaustion markers on the T cells and aimed to produce T cells with a 
favorable phenotype (18, 19) and high proliferative capacity upon repetitive antigen encounter. 
2.2.2 Methods and Results 
CD19 CAR T cells were successfully generated from peripheral blood of four pediatric patients 
using the CliniMACS Prodigy. T cells were isolated using CD4/CD8 microbeads, activated, 
lentivirally transduced with a 2nd generation CD19 CAR (4-1BB/CD3zeta) and expanded until day 
12 after activation. CAR T-cell manufacturing at clinical scale was successful in 4/4 patients. The 
final product showed a mean transduction rate of 27% and a T-cell phenotype of mostly stem cell-
like and central memory T cells. Leukemic blasts were not detectable in the final product, although 
2/4 patients had >60% leukemic cells in their peripheral blood at timepoint of sample collection. 
Expression of exhaustion/co-inhibitory markers in the final product was low except for TIM-3 (T-
cell immunoglobulin and mucin-domain containing-3). T cells from the final product showed high 
anti-leukemic functionality in vitro and strong proliferative capacity even after multiple antigen 
encounter. CAR T cells displayed a strong Th1 cytokine profile with increased secretion of IFN- 
(Interferon gamma), TNF- (Tumor Necrosis Factor alpha), IL-2 (Interleukin-2) and GM-CSF 
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(Granulocyte-Macrophage Colony-Stimulating Factor). IL-6 production was low supporting 
previous reports that CAR T cells are not the major source of IL-6 in clinical CRS (20). CAR T-
cell counts in the final product would have been sufficient to treat a 100 kg patient with a dose of 
up to 5e6 CAR T cells/kg body weight. In conclusion, CD19 CAR T-cell generation in a partly 
automated closed system for GMP-grade manufacturing was successful and yielded highly 
functional CAR T cells even from small pediatric patient samples. 
2.2.3 Discussion 
Automated and standardized manufacturing of CAR T-cell products at clinical scale has been 
challenging in the past and a variety of different production and expansion protocols have been 
utilized. Here, we verified that a partly automated closed system (15, 16) can be used even when 
starting with complex patient samples which consist of a variety of different cell types including 
leukemic blasts. Until now, CAR T-cell generation is still routinely done by using leukapheresis 
products from patients, a process which can be complicated due to the clinical situation of the 
patients. In this paper, we showed that peripheral blood as initial source can be used at least in 
older children. The presence of leukemic blasts in the leukapheresis or initial blood product can 
be concerning according to case reports about potential viral transduction of malignant B cells 
and subsequent CD19- relapse in patients (9). In our study, we weren’t able to detect leukemic 
blasts at the end of the culture process, but as the staining was done with a conventional CD19 
antibody and due to limited sensitivity of flow cytometry, we cannot fully exclude that this 
phenomenon can happen in patient samples with remaining blasts at timepoint of production start. 
Thus, optimizing the T-cell selection protocols for these patients is crucial. Besides remaining 
leukemic cells, patient samples can be challenging for a variety of other reasons such as non-
homogenous starting material and T-cell exhaustion due to prior treatment. Nevertheless, our 
study has shown that CAR T-cell production using the CliniMACS Prodigy is feasible not only 
using samples from healthy donors but also with more complex patient samples. T cells in the 
final product showed high anti-leukemic functionality and proliferative potential as well as low 
expression of inhibitory molecules except for TIM-3. The CliniMACS Prodigy has since been used 
to produce CARs with a variety of specificities and clinical studies are ongoing (21, 22). 
2.3 Paper II: The role of TIM-3 for anti-leukemic T-cell 
responses 
2.3.1 Introduction 
Although pediatric leukemia is considered a malignancy with low immunogenicity and low 
mutational load (23), earlier studies from our group had shown that leukemic cells can 
overexpress both, co-stimulatory and co-inhibitory immune checkpoint molecules (24). Moreover, 
bone marrow T cells of pediatric BCP-ALL patients can overexpress PD-1 (Programmed cell 
death protein 1) and TIM-3 and this expression can be increased by induction of a T-cell response 
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using the bispecific T-cell engager Blinatumomab (anti-CD3/CD19) (24). Thus, we were 
interested in more systematically studying the role of co-inhibitory immune checkpoints for 
prognosis and treatment of pediatric BCP-ALL. TIM-3 was in particular interesting because we 
had observed high TIM-3 expression on CAR T cells in paper I and TIM-3 (together with PD-1) 
was described to be overexpressed and associated with dismal prognosis in adult acute myeloid 
leukemia (AML) (25). TIM-3 has first been identified as an anti-inflammatory immune checkpoint 
on CD4+ and CD8+ T cells (26). Its known binding partners are HMGB1 (high mobility group box 
1 protein), PtdSer (phosphatidylserine), CEACAM-1 (carcinoembryonic antigen-related cell 
adhesion molecule 1) and Galectin-9 (27-29). TIM-3 expression can be upregulated by 
inflammatory cytokines such as IL-2, -7, -12, -15, -21, -27 and TGF- (Transforming Growth 
Factor beta) (30-33). TIM-3 is essential for immune tolerance in the context of auto-inflammatory 
disease and TIM-3 blockade by antibodies can lead to macrophage activation and experimental 
autoimmune encephalitis (26, 34, 35). In the context of chronic viral infections, TIM-3 was found 
to be expressed on exhausted and dysfunctional CD8+ T cells (36, 37). In malignant disease, 
increased TIM-3 expression was observed on tumor-infiltrating lymphocytes in a variety of 
different solid tumors and was associated with T-cell dysfunction (38-40). Right before submission 
of this paper, presence of PD-1+/TIM-3+ CD4+ T cells was shown to define a patient group with 
dismal prognosis in adult ALL (41), but TIM-3 expression had not been systematically studied in 
bone marrow samples from pediatric BCP-ALL before. 
2.3.2 Methods and Results 
We characterized leukemic cells and bone marrow T cells from 100 pediatric BCP-ALL patients 
and 13 healthy controls by flow cytometry and RNA sequencing. Follow-up data including relapse-
free survival was available for all patient samples (median follow up of 7.8 years). Bone marrow 
was taken at timepoint of initial diagnosis before start of treatment. We found that CD4/CD8 ratio 
of bone marrow T cells was shifted toward a predominance of CD4+ cells in the bone marrow of 
patients compared to healthy controls. Moreover, we found significantly higher percentages of 
terminally differentiated CD62L-/CD45RO- T cells in the bone marrow of patients. PD-1 and TIM-
3 were not significantly upregulated on T cells of BCP-ALL patients, but patients with future 
relapse of leukemia had a significantly higher proportion of TIM-3+/CD4+ T cells in their bone 
marrow at timepoint of initial diagnosis compared to patients who will survive in complete 
remission. We thus evaluated the predictive value of TIM-3 expression (with or without co-
expression of PD-1) for relapse-free survival of BCP-ALL patients. We found that TIM-3 
expression alone (as well as in combination with PD-1 expression, but not PD-1 expression alone) 
can predict future ALL relapse with a hazard ratio of 7.1. We next confirmed that contact with 
leukemic blasts and induction of a T-cell response by Blinatumomab can induce TIM-3 expression 
on primary human T cells. We used CRISPR/Cas9 technology to knock out (KO) TIM-3 
expression in primary human T cells and found that TIM-3 KO increases activation and 
proliferation in T cells while viral overexpression of TIM-3 leads to decreased proliferative potential 
of T cells in response to leukemic blasts. RNA sequencing of patients’ bone marrow samples 
revealed that – while known inducers and ligands of TIM-3 were not differentially expressed 
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between TIM-3 high vs low bone marrow samples – the co-inhibitory immune checkpoint CD200 
was significantly upregulated in leukemia cells derived from TIM-3 overexpressing bone marrow 
samples (multiple testing correction performed for the 21 immune-regulatory genes tested in this 
analysis). We indeed found that CD200 is highly overexpressed on leukemic cells compared to 
physiological precursors and that CD200 expression on leukemic cells can decrease activation 
potential of anti-leukemic T cells. Moreover, we observed a subtle but statistically significant 
overexpression of TIM-3 on CD4+ T cells induced by contact with CD200+ leukemic cells both on 
transcriptional and protein expression level. 
2.3.3 Discussion 
Although pediatric leukemia is considered a malignancy of low immunogenicity, we found that T 
cells are present in the bone marrow of pediatric BCP-ALL patients and show a more terminally 
differentiated phenotype compared to healthy controls. Further studies have to elucidate whether 
the altered phenotype would have been detectable prior to diagnosis and could represent a risk 
factor for developing a hematologic malignancy, or whether leukemia itself induced terminal 
differentiation in T cells. Moreover, we found that TIM-3 expression on CD4+ bone marrow T cells 
of pediatric patients can reliably predict leukemia relapse. Despite slightly lower statistical 
significance of prediction based on TIM-3 expression compared to the conventionally used 
prediction marker MRD (minimal residual disease), the hazard ratio was comparable (7.12-fold 
increased risk for TIM-3 high patients vs 7.98-fold increased risk defined by MRD quantification 
in this cohort). In our study, RNA sequencing analysis suggested that TIM-3 expression in bone 
marrow T cells was not upregulated by known inducers but was associated with elevated CD200 
expression on leukemic cells. CD200 overexpression was observed in a variety of different solid 
tumors as well as in leukemia (42-45). It’s known interaction partner, CD200 receptor (CD200R), 
is expressed on antigen presenting cells (APCs) and T cells and binding of CD200 can lead to 
decreased T-cell function (46). More mechanistic insight is needed regarding whether TIM-3 can 
directly be induced by CD200 or if there is an indirect mechanism leading to the subtle TIM-3 
overexpression we observed in this study. Moreover, it is unclear whether CD200 can only 
increase TIM-3 expression (directly or indirectly) or if it can also mediate TIM-3 function. 
Nevertheless, we confirmed that TIM-3 overexpression decreases T-cell activation whereas TIM-
3 KO improves activation and proliferation capacity of anti-leukemic T cells. In conclusion, the 
data showed that BCP-ALL is associated with late T-cell differentiation states and suggested that 
the TIM-3 axis constitutes a mechanism of immune dysregulation in BCP-ALL. This finding is not 
only important to better understand the potential interaction of leukemic cells and bone marrow T 
cells but can also inform future therapeutic approaches. It underlines the rationale for testing e.g. 
TIM-3 KO CD19 CAR T cells, checkpoint blockade with anti-TIM-3 or administration of T cells 
with e.g. TIM-3/CD28 fusion receptors which are meant to turn TIM-3-mediated inhibition into T-
cell activation through CD28. 
Immunotherapy of pediatric acute lymphoblastic B-cell leukemia using gene-modified T cells 17 
2.4 Conclusion and Outlook 
Clinical treatment of pediatric BCP-ALL involves chemotherapy and – in case of high-risk 
leukemia or relapse – treatment with the bi-specific T-cell engager Blinatumomab and 
hematopoietic stem-cell transplantation. CD19 CAR T cells are currently approved for refractory 
disease or after multiple relapses. Administration of CD19 CAR T cells as an earlier line in BCP-
ALL therapy is investigated in clinical trials. Despite high initial response rates after treatment with 
CD19 CARs, long-term event-free survival decreases to about 50% in pediatric BCP-ALL patients 
(6, 7). Clinical trials are investigating combination therapies of CAR T cells with checkpoint 
blockade, but checkpoint blockade alone so far had only limited success in malignancies with low 
immunogenicity/mutational load such as pediatric BCP-ALL (47, 48). To improve current 
treatment of pediatric BCP-ALL, it is not only important to optimize and standardize production 
protocols (as shown in paper I), but also to better understand the interaction of leukemic cells with 
bone marrow T cells (as shown in paper II). Understanding that, although dealing with a low-
immunogenic malignancy, immune checkpoint axes can play a role for prognosis and treatment 
of pediatric leukemia is crucial for hypothesis-driven development of new immunotherapeutic 
approaches. In currently unpublished data, we pursued the therapeutic role of immune 
checkpoints and found that CD19 CAR T cells with TIM-3 KO or with additional overexpression 
of TIM-3/CD28 or PD-1/CD28 fusion receptors (49) are better able to control leukemia than 
conventional CAR T-cell approaches. We hope that a better insight into the interplay of 
therapeutic and physiologic T cells with leukemic cells can inform future translational research 
projects and ultimately lead to better CAR T-cell therapies.  
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3. Paper I 
Material from: Blaeschke et al., “Induction of a central memory and stem cell memory phenotype 
in functionally active CD4+ and CD8+ CAR T cells produced in an automated good manufacturing 
practice system for the treatment of CD19+ acute lymphoblastic leukemia”, Cancer Immunology, 
Immunotherapy, published 2018, Springer Nature 
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4. Paper II 
Material from: Blaeschke et al., “Leukemia-induced dysfunctional TIM-3+CD4+ bone marrow T 




Immunotherapy of pediatric acute lymphoblastic B-cell leukemia using gene-modified T cells 33 
 
  
Immunotherapy of pediatric acute lymphoblastic B-cell leukemia using gene-modified T cells 34 
 
  
Immunotherapy of pediatric acute lymphoblastic B-cell leukemia using gene-modified T cells 35 
 
  
Immunotherapy of pediatric acute lymphoblastic B-cell leukemia using gene-modified T cells 36 
 
  
Immunotherapy of pediatric acute lymphoblastic B-cell leukemia using gene-modified T cells 37 
 
  
Immunotherapy of pediatric acute lymphoblastic B-cell leukemia using gene-modified T cells 38 
 
  
Immunotherapy of pediatric acute lymphoblastic B-cell leukemia using gene-modified T cells 39 
 
  
Immunotherapy of pediatric acute lymphoblastic B-cell leukemia using gene-modified T cells 40 
 
  
Immunotherapy of pediatric acute lymphoblastic B-cell leukemia using gene-modified T cells 41 
 
  
Immunotherapy of pediatric acute lymphoblastic B-cell leukemia using gene-modified T cells 42 
 
  
Immunotherapy of pediatric acute lymphoblastic B-cell leukemia using gene-modified T cells 43 
 
  
Immunotherapy of pediatric acute lymphoblastic B-cell leukemia using gene-modified T cells 44 
 
  
Immunotherapy of pediatric acute lymphoblastic B-cell leukemia using gene-modified T cells 45 
 
  
Immunotherapy of pediatric acute lymphoblastic B-cell leukemia using gene-modified T cells 46 
References 
1. Lee DW, Kochenderfer JN, Stetler-Stevenson M, Cui YK, Delbrook C, Feldman SA, Fry TJ, 
Orentas R, Sabatino M, Shah NN, Steinberg SM, Stroncek D, Tschernia N, Yuan C, Zhang H, 
Zhang L, Rosenberg SA, Wayne AS, Mackall CL. 2015. T cells expressing CD19 chimeric antigen 
receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-
escalation trial. Lancet;385(9967):517-28. 
2. Maude SL, Frey N, Shaw PA, Aplenc R, Barrett DM, Bunin NJ, Chew A, Gonzalez VE, Zheng 
Z, Lacey SF, Mahnke YD, Melenhorst JJ, Rheingold SR, Shen A, Teachey DT, Levine BL, June 
CH, Porter DL, Grupp SA. 2014. Chimeric antigen receptor T cells for sustained remissions in 
leukemia. N Engl J Med;371(16):1507-17. 
3. Sadelain M, Brentjens R, Riviere I. 2013. The basic principles of chimeric antigen receptor 
design. Cancer Discov;3(4):388-98. 
4. Bouchkouj N, Kasamon YL, de Claro RA, George B, Lin X, Lee S, Blumenthal GM, Bryan W, 
McKee AE, Pazdur R. 2019. FDA Approval Summary: Axicabtagene Ciloleucel for Relapsed or 
Refractory Large B-cell Lymphoma. Clin Cancer Res;25(6):1702-8. 
5. O'Leary MC, Lu X, Huang Y, Lin X, Mahmood I, Przepiorka D, Gavin D, Lee S, Liu K, George 
B, Bryan W, Theoret MR, Pazdur R. 2019. FDA Approval Summary: Tisagenlecleucel for 
Treatment of Patients with Relapsed or Refractory B-cell Precursor Acute Lymphoblastic 
Leukemia. Clin Cancer Res;25(4):1142-6. 
6. Gardner RA, Finney O, Annesley C, Brakke H, Summers C, Leger K, Bleakley M, Brown C, 
Mgebroff S, Kelly-Spratt KS, Hoglund V, Lindgren C, Oron AP, Li D, Riddell SR, Park JR, Jensen 
MC. 2017. Intent-to-treat leukemia remission by CD19 CAR T cells of defined formulation and 
dose in children and young adults. Blood;129(25):3322-31. 
7. Maude SL, Laetsch TW, Buechner J, Rives S, Boyer M, Bittencourt H, Bader P, Verneris MR, 
Stefanski HE, Myers GD, Qayed M, De Moerloose B, Hiramatsu H, Schlis K, Davis KL, Martin PL, 
Nemecek ER, Yanik GA, Peters C, Baruchel A, Boissel N, Mechinaud F, Balduzzi A, Krueger J, 
June CH, Levine BL, Wood P, Taran T, Leung M, Mueller KT, Zhang Y, Sen K, Lebwohl D, 
Pulsipher MA, Grupp SA. 2018. Tisagenlecleucel in Children and Young Adults with B-Cell 
Lymphoblastic Leukemia. N Engl J Med;378(5):439-48. 
8. Seimetz D, Heller K, Richter J. 2019. Approval of First CAR-Ts: Have we Solved all Hurdles 
for ATMPs? Cell Med;11:2155179018822781. 
9. Ruella M, Xu J, Barrett DM, Fraietta JA, Reich TJ, Ambrose DE, Klichinsky M, Shestova O, 
Patel PR, Kulikovskaya I, Nazimuddin F, Bhoj VG, Orlando EJ, Fry TJ, Bitter H, Maude SL, Levine 
BL, Nobles CL, Bushman FD, Young RM, Scholler J, Gill SI, June CH, Grupp SA, Lacey SF, 
Melenhorst JJ. 2018. Induction of resistance to chimeric antigen receptor T cell therapy by 
transduction of a single leukemic B cell. Nat Med;24(10):1499-503. 
10. Orlando EJ, Han X, Tribouley C, Wood PA, Leary RJ, Riester M, Levine JE, Qayed M, Grupp 
SA, Boyer M, De Moerloose B, Nemecek ER, Bittencourt H, Hiramatsu H, Buechner J, Davies 
SM, Verneris MR, Nguyen K, Brogdon JL, Bitter H, Morrissey M, Pierog P, Pantano S, Engelman 
JA, Winckler W. 2018. Genetic mechanisms of target antigen loss in CAR19 therapy of acute 
lymphoblastic leukemia. Nat Med;24(10):1504-6. 
11. Shah NN, Fry TJ. 2019. Mechanisms of resistance to CAR T cell therapy. Nat Rev Clin 
Oncol;16(6):372-85. 
12. Tokarew N, Ogonek J, Endres S, von Bergwelt-Baildon M, Kobold S. 2019. Teaching an old 
dog new tricks: next-generation CAR T cells. Br J Cancer;120(1):26-37. 
13. Hollyman D, Stefanski J, Przybylowski M, Bartido S, Borquez-Ojeda O, Taylor C, Yeh R, 
Capacio V, Olszewska M, Hosey J, Sadelain M, Brentjens RJ, Riviere I. 2009. Manufacturing 
validation of biologically functional T cells targeted to CD19 antigen for autologous adoptive cell 
therapy. J Immunother;32(2):169-80. 
14. Bajgain P, Mucharla R, Wilson J, Welch D, Anurathapan U, Liang B, Lu X, Ripple K, Centanni 
JM, Hall C, Hsu D, Couture LA, Gupta S, Gee AP, Heslop HE, Leen AM, Rooney CM, Vera JF. 
2014. Optimizing the production of suspension cells using the G-Rex "M" series. Mol Ther 
Methods Clin Dev;1:14015. 
Immunotherapy of pediatric acute lymphoblastic B-cell leukemia using gene-modified T cells 47 
15. Mock U, Nickolay L, Philip B, Cheung GW, Zhan H, Johnston ICD, Kaiser AD, Peggs K, Pule 
M, Thrasher AJ, Qasim W. 2016. Automated manufacturing of chimeric antigen receptor T cells 
for adoptive immunotherapy using CliniMACS prodigy. Cytotherapy;18(8):1002-11. 
16. Schneider D, Xiong Y, Wu D, Nlle V, Schmitz S, Haso W, Kaiser A, Dropulic B, Orentas RJ. 
2017. A tandem CD19/CD20 CAR lentiviral vector drives on-target and off-target antigen 
modulation in leukemia cell lines. J Immunother Cancer;5:42. 
17. Maude S, Barrett DM. 2016. Current status of chimeric antigen receptor therapy for 
haematological malignancies. Br J Haematol;172(1):11-22. 
18. Wang X, Popplewell LL, Wagner JR, Naranjo A, Blanchard MS, Mott MR, Norris AP, Wong 
CW, Urak RZ, Chang WC, Khaled SK, Siddiqi T, Budde LE, Xu J, Chang B, Gidwaney N, Thomas 
SH, Cooper LJ, Riddell SR, Brown CE, Jensen MC, Forman SJ. 2016. Phase 1 studies of central 
memory-derived CD19 CAR T-cell therapy following autologous HSCT in patients with B-cell 
NHL. Blood;127(24):2980-90. 
19. Gattinoni L, Lugli E, Ji Y, Pos Z, Paulos CM, Quigley MF, Almeida JR, Gostick E, Yu Z, 
Carpenito C, Wang E, Douek DC, Price DA, June CH, Marincola FM, Roederer M, Restifo NP. 
2011. A human memory T cell subset with stem cell-like properties. Nat Med;17(10):1290-7. 
20. Giavridis T, van der Stegen SJC, Eyquem J, Hamieh M, Piersigilli A, Sadelain M. 2018. CAR 
T cell-induced cytokine release syndrome is mediated by macrophages and abated by IL-1 
blockade. Nat Med;24(6):731-8. 
21. Jackson Z, Roe A, Sharma AA, Lopes F, Talla A, Kleinsorge-Block S, Zamborsky K, 
Schiavone J, Manjappa S, Schauner R, Lee G, Liu R, Caimi PF, Xiong Y, Krueger W, Worden A, 
Kadan M, Schneider D, Orentas R, Dropulic B, Sekaly RP, de Lima M, Wald DN, Reese JS. 2020. 
Automated Manufacture of Autologous CD19 CAR-T Cells for Treatment of Non-hodgkin 
Lymphoma. Front Immunol;11:1941. 
22. Fernandez L, Fernandez A, Mirones I, Escudero A, Cardoso L, Vela M, Lanzarot D, de Paz 
R, Leivas A, Gallardo M, Marcos A, Romero AB, Martinez-Lopez J, Perez-Martinez A. 2019. 
GMP-Compliant Manufacturing of NKG2D CAR Memory T Cells Using CliniMACS Prodigy. Front 
Immunol;10:2361. 
23. Grobner SN, Worst BC, Weischenfeldt J, Buchhalter I, Kleinheinz K, Rudneva VA, Johann 
PD, Balasubramanian GP, Segura-Wang M, Brabetz S, Bender S, Hutter B, Sturm D, Pfaff E, 
Hubschmann D, Zipprich G, Heinold M, Eils J, Lawerenz C, Erkek S, Lambo S, Waszak S, 
Blattmann C, Borkhardt A, Kuhlen M, Eggert A, Fulda S, Gessler M, Wegert J, Kappler R, 
Baumhoer D, Burdach S, Kirschner-Schwabe R, Kontny U, Kulozik AE, Lohmann D, Hettmer S, 
Eckert C, Bielack S, Nathrath M, Niemeyer C, Richter GH, Schulte J, Siebert R, Westermann F, 
Molenaar JJ, Vassal G, Witt H, Project IP-S, Project IM-S, Burkhardt B, Kratz CP, Witt O, van 
Tilburg CM, Kramm CM, Fleischhack G, Dirksen U, Rutkowski S, Fruhwald M, von Hoff K, Wolf 
S, Klingebiel T, Koscielniak E, Landgraf P, Koster J, Resnick AC, Zhang J, Liu Y, Zhou X, 
Waanders AJ, Zwijnenburg DA, Raman P, Brors B, Weber UD, Northcott PA, Pajtler KW, Kool M, 
Piro RM, Korbel JO, Schlesner M, Eils R, Jones DTW, Lichter P, Chavez L, Zapatka M, Pfister 
SM. 2018. The landscape of genomic alterations across childhood cancers. 
Nature;555(7696):321-7. 
24. Feucht J, Kayser S, Gorodezki D, Hamieh M, Doring M, Blaeschke F, Schlegel P, Bosmuller 
H, Quintanilla-Fend L, Ebinger M, Lang P, Handgretinger R, Feuchtinger T. 2016. T-cell 
responses against CD19+ pediatric acute lymphoblastic leukemia mediated by bispecific T-cell 
engager (BiTE) are regulated contrarily by PD-L1 and CD80/CD86 on leukemic blasts. 
Oncotarget;7(47):76902-19. 
25. Kong Y, Zhang J, Claxton DF, Ehmann WC, Rybka WB, Zhu L, Zeng H, Schell TD, Zheng H. 
2015. PD-1(hi)TIM-3(+) T cells associate with and predict leukemia relapse in AML patients post 
allogeneic stem cell transplantation. Blood Cancer J;5:e330. 
26. Monney L, Sabatos CA, Gaglia JL, Ryu A, Waldner H, Chernova T, Manning S, Greenfield 
EA, Coyle AJ, Sobel RA, Freeman GJ, Kuchroo VK. 2002. Th1-specific cell surface protein Tim-
3 regulates macrophage activation and severity of an autoimmune disease. 
Nature;415(6871):536-41. 
Immunotherapy of pediatric acute lymphoblastic B-cell leukemia using gene-modified T cells 48 
27. Zhu C, Anderson AC, Schubart A, Xiong H, Imitola J, Khoury SJ, Zheng XX, Strom TB, 
Kuchroo VK. 2005. The Tim-3 ligand galectin-9 negatively regulates T helper type 1 immunity. 
Nat Immunol;6(12):1245-52. 
28. Chiba S, Baghdadi M, Akiba H, Yoshiyama H, Kinoshita I, Dosaka-Akita H, Fujioka Y, Ohba 
Y, Gorman JV, Colgan JD, Hirashima M, Uede T, Takaoka A, Yagita H, Jinushi M. 2012. Tumor-
infiltrating DCs suppress nucleic acid-mediated innate immune responses through interactions 
between the receptor TIM-3 and the alarmin HMGB1. Nat Immunol;13(9):832-42. 
29. Huang YH, Zhu C, Kondo Y, Anderson AC, Gandhi A, Russell A, Dougan SK, Petersen BS, 
Melum E, Pertel T, Clayton KL, Raab M, Chen Q, Beauchemin N, Yazaki PJ, Pyzik M, Ostrowski 
MA, Glickman JN, Rudd CE, Ploegh HL, Franke A, Petsko GA, Kuchroo VK, Blumberg RS. 2015. 
CEACAM1 regulates TIM-3-mediated tolerance and exhaustion. Nature;517(7534):386-90. 
30. Mujib S, Jones RB, Lo C, Aidarus N, Clayton K, Sakhdari A, Benko E, Kovacs C, Ostrowski 
MA. 2012. Antigen-independent induction of Tim-3 expression on human T cells by the common 
gamma-chain cytokines IL-2, IL-7, IL-15, and IL-21 is associated with proliferation and is 
dependent on the phosphoinositide 3-kinase pathway. J Immunol;188(8):3745-56. 
31. Yang ZZ, Grote DM, Ziesmer SC, Niki T, Hirashima M, Novak AJ, Witzig TE, Ansell SM. 2012. 
IL-12 upregulates TIM-3 expression and induces T cell exhaustion in patients with follicular B cell 
non-Hodgkin lymphoma. J Clin Invest;122(4):1271-82. 
32. Zhu C, Sakuishi K, Xiao S, Sun Z, Zaghouani S, Gu G, Wang C, Tan DJ, Wu C, Rangachari 
M, Pertel T, Jin HT, Ahmed R, Anderson AC, Kuchroo VK. 2015. An IL-27/NFIL3 signalling axis 
drives Tim-3 and IL-10 expression and T-cell dysfunction. Nat Commun;6:6072. 
33. Wiener Z, Kohalmi B, Pocza P, Jeager J, Tolgyesi G, Toth S, Gorbe E, Papp Z, Falus A. 
2007. TIM-3 is expressed in melanoma cells and is upregulated in TGF-beta stimulated mast 
cells. J Invest Dermatol;127(4):906-14. 
34. Sabatos CA, Chakravarti S, Cha E, Schubart A, Sanchez-Fueyo A, Zheng XX, Coyle AJ, 
Strom TB, Freeman GJ, Kuchroo VK. 2003. Interaction of Tim-3 and Tim-3 ligand regulates T 
helper type 1 responses and induction of peripheral tolerance. Nat Immunol;4(11):1102-10. 
35. Sanchez-Fueyo A, Tian J, Picarella D, Domenig C, Zheng XX, Sabatos CA, Manlongat N, 
Bender O, Kamradt T, Kuchroo VK, Gutierrez-Ramos JC, Coyle AJ, Strom TB. 2003. Tim-3 
inhibits T helper type 1-mediated auto- and alloimmune responses and promotes immunological 
tolerance. Nat Immunol;4(11):1093-101. 
36. Jin HT, Anderson AC, Tan WG, West EE, Ha SJ, Araki K, Freeman GJ, Kuchroo VK, Ahmed 
R. 2010. Cooperation of Tim-3 and PD-1 in CD8 T-cell exhaustion during chronic viral infection. 
Proc Natl Acad Sci U S A;107(33):14733-8. 
37. Jones RB, Ndhlovu LC, Barbour JD, Sheth PM, Jha AR, Long BR, Wong JC, Satkunarajah 
M, Schweneker M, Chapman JM, Gyenes G, Vali B, Hyrcza MD, Yue FY, Kovacs C, Sassi A, 
Loutfy M, Halpenny R, Persad D, Spotts G, Hecht FM, Chun TW, McCune JM, Kaul R, Rini JM, 
Nixon DF, Ostrowski MA. 2008. Tim-3 expression defines a novel population of dysfunctional T 
cells with highly elevated frequencies in progressive HIV-1 infection. J Exp Med;205(12):2763-
79. 
38. Fourcade J, Sun Z, Benallaoua M, Guillaume P, Luescher IF, Sander C, Kirkwood JM, 
Kuchroo V, Zarour HM. 2010. Upregulation of Tim-3 and PD-1 expression is associated with 
tumor antigen-specific CD8+ T cell dysfunction in melanoma patients. J Exp Med;207(10):2175-
86. 
39. Gao X, Zhu Y, Li G, Huang H, Zhang G, Wang F, Sun J, Yang Q, Zhang X, Lu B. 2012. TIM-
3 expression characterizes regulatory T cells in tumor tissues and is associated with lung cancer 
progression. PLoS One;7(2):e30676. 
40. Anderson AC, Joller N, Kuchroo VK. 2016. Lag-3, Tim-3, and TIGIT: Co-inhibitory Receptors 
with Specialized Functions in Immune Regulation. Immunity;44(5):989-1004. 
41. Hohtari H, Bruck O, Blom S, Turkki R, Sinisalo M, Kovanen PE, Kallioniemi O, Pellinen T, 
Porkka K, Mustjoki S. 2019. Immune cell constitution in bone marrow microenvironment predicts 
outcome in adult ALL. Leukemia;33(7):1570-82. 
Immunotherapy of pediatric acute lymphoblastic B-cell leukemia using gene-modified T cells 49 
42. Stumpfova M, Ratner D, Desciak EB, Eliezri YD, Owens DM. 2010. The immunosuppressive 
surface ligand CD200 augments the metastatic capacity of squamous cell carcinoma. Cancer 
Res;70(7):2962-72. 
43. Petermann KB, Rozenberg GI, Zedek D, Groben P, McKinnon K, Buehler C, Kim WY, Shields 
JM, Penland S, Bear JE, Thomas NE, Serody JS, Sharpless NE. 2007. CD200 is induced by ERK 
and is a potential therapeutic target in melanoma. J Clin Invest;117(12):3922-9. 
44. Palumbo GA, Parrinello N, Fargione G, Cardillo K, Chiarenza A, Berretta S, Conticello C, 
Villari L, Di Raimondo F. 2009. CD200 expression may help in differential diagnosis between 
mantle cell lymphoma and B-cell chronic lymphocytic leukemia. Leuk Res;33(9):1212-6. 
45. Coles SJ, Gilmour MN, Reid R, Knapper S, Burnett AK, Man S, Tonks A, Darley RL. 2015. 
The immunosuppressive ligands PD-L1 and CD200 are linked in AML T-cell immunosuppression: 
identification of a new immunotherapeutic synapse. Leukemia;29(9):1952-4. 
46. Ring EK, Markert JM, Gillespie GY, Friedman GK. 2017. Checkpoint Proteins in Pediatric 
Brain and Extracranial Solid Tumors: Opportunities for Immunotherapy. Clin Cancer 
Res;23(2):342-50. 
47. Rizvi NA, Hellmann MD, Snyder A, Kvistborg P, Makarov V, Havel JJ, Lee W, Yuan J, Wong 
P, Ho TS, Miller ML, Rekhtman N, Moreira AL, Ibrahim F, Bruggeman C, Gasmi B, Zappasodi R, 
Maeda Y, Sander C, Garon EB, Merghoub T, Wolchok JD, Schumacher TN, Chan TA. 2015. 
Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small 
cell lung cancer. Science;348(6230):124-8. 
48. Park JA, Cheung NV. 2017. Limitations and opportunities for immune checkpoint inhibitors in 
pediatric malignancies. Cancer Treat Rev;58:22-33. 
49. Kobold S, Grassmann S, Chaloupka M, Lampert C, Wenk S, Kraus F, Rapp M, Duwell P, 
Zeng Y, Schmollinger JC, Schnurr M, Endres S, Rothenfusser S. 2015. Impact of a New Fusion 




Immunotherapy of pediatric acute lymphoblastic B-cell leukemia using gene-modified T cells 50 
Acknowledgements 
I would like to thank 
- Prof. Tobias Feuchtinger, Prof. Sebastian Kobold and Prof. Dirk Busch for supervising 
this thesis, their great support and helpful feedback. 
- The entire Feuchtinger Lab (especially Dana Stenger, the technicians Tanja Weisser, 
Nicola Habjan, Nadine Stoll, the other postdocs, as well as the MD students I had the 
privilege to mentor). 
- Prof. Alex Marson and his lab for an outstanding postdoc experience despite unexpected 
global challenges. 
- The colleagues at Miltenyi Biotec who contributed to the first part of this thesis. 
- The COALL study center for providing patient samples and follow up data. 
- The healthy blood donors. 
- All our collaborators and funding sources. 
- My mentors and research colleagues I had the privilege to work with in the past. 
- My clinical colleagues. 
- My friends and family. 
- The young patients who contributed to this study and were willing to donate blood for 
research despite just being diagnosed with leukemia. I am deeply impressed by your 
courage and resilience. 
